NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
28 Nov 2017

MedLumics Appoints Medtech Industry Veterans James Greene as Chief Executive Officer and Giovanni Leo as Member of the Board of Directors

MedLumics, announced today it has appointed James Greene as Chief Executive Officer and named Giovanni Leo to the board of directors.
Xeltis Closes €45 Million in Oversubscribed Series C Financing to Advance Aortic and Pulmonary Valve Programs<
15 Nov 2017

Xeltis Closes €45 Million in Oversubscribed Series C Financing to Advance Aortic and Pulmonary Valve Programs

The funding round was led by a global strategic investor with participation from venture capital fund Ysios Capital and a number of large private investors.
09 Nov 2017

CorWave Receives 2017 Deloitte ‘Technology Fast 50 Biotech of the Future’ Award of the Parisian Region

CorWave, announced today that it received the 'Deloitte In Extenso Technology Fast 50 Biotech of the Future' award for the Parisian Region.
07 Nov 2017

Kala Pharmaceuticals Reports Third Quarter 2017 Financial Results And Provides Business Update

Kala Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2017 and provided an update on business progress.
New Clinical Data from Aura Biosciences to be Featured in Presentation at the American Academy of Ophthalmology 2017 Annual Meeting<
25 Oct 2017

New Clinical Data from Aura Biosciences to be Featured in Presentation at the American Academy of Ophthalmology 2017 Annual Meeting

Late-breaking session to highlight Phase 1b clinical trial data for light-activated AU-011 for the treatment of primary ocular melanoma.
25 Oct 2017

Kala Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for INVELTYSTM (KPI-121 1%)

Kala Pharmaceuticals, Inc. today announced that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration for INVELTYSTM (KPI-121 1%).
Phase 3 prospective/retrospective study of MAFTest® in Lancet Oncology demonstrates the effect of MAF gene amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer<
19 Oct 2017

Phase 3 prospective/retrospective study of MAFTest® in Lancet Oncology demonstrates the effect of MAF gene amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer

MAFTest® negative status in patients treated with zoledronic acid in the adjuvant setting was associated with improved invasive-disease-free survival and overall survival.

AELIX Therapeutics appoints Dr. Thomas Hecht as Chairman of the Board of Directors<
18 Oct 2017

AELIX Therapeutics appoints Dr. Thomas Hecht as Chairman of the Board of Directors

Dr. Hecht joins the company as the first patient has been enrolled in the company’s phase I clinical trial for the assessment of its proprietary HTI vaccine.

12 Oct 2017

Dr Bastian Dehmel Appointed CMO of OxThera

OxThera AB, today announced the appointment of Dr Bastian Dehmel as their new Chief Medical Officer.
27 Sep 2017

FierceBiotech names Vivet Therapeutics as one of its 2017 “Fierce 15” Biotech Companies

Vivet Therapeutics is proud to announce that it has been named by FierceBiotech as one of 2017's Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.